What Is the Caremark 25% Aberrancy Line?
Short answer
A 25% aberrancy reference line is commonly discussed when reviewing the share of a pharmacy's business tied to defined aberrant products. PharmaFix presents report-based paid-dollar and claim-count estimates; current payer documents and the pharmacy's agreement control.
Why it matters
Networks may review dispensing mix under their own current terms and methods. PharmaFix helps a pharmacy review report-based rates before reconciliation, but it does not predict payer action or determine contractual compliance.
How it works
- Dollar test: aberrant paid dollars divided by total paid dollars, for the month.
- Claim-count test: aberrant claims divided by total claims, for the month.
- The share is cumulative across the month and resets at the start of the next.
Because the share is cumulative, one busy aberrant day early in the month affects the rest of the month until volume catches up. That is why a mid-month read is more useful than waiting for the statement.
Quick reference
| Term | Meaning |
|---|---|
| The 25% reference line | A comparison point used by this analyzer; current payer documents and the pharmacy's agreement control. |
| Dollar test | Aberrant paid dollars ÷ total paid dollars, month to date. |
| Claim-count test | Aberrant claims ÷ total claims, month to date. |
| Effective rate | Your cumulative aberrant share so far this month. |
| Room remaining | A mathematical estimate of the distance to the 25% reference line under the analyzer's assumptions. |
Scope and limitations
This article is general product information, not legal, clinical, contracting, audit, or dispensing advice. PharmaFix uses the supported fields and bundled reference data described in the product; it does not speak for any payer or guarantee that a payer will calculate or act the same way. Review current network documents and obtain professional advice where appropriate.
A simple example
Suppose a pharmacy has $90,000 in total paid claims for the month and $5,400 tied to aberrant NDCs. The dollar-test share is 5,400 / 90,000 = 6.0%, comfortably under the 25% line. If aberrant paid rose to $22,500 on the same $90,000, the share would be 25% — at the line.
Illustrative figures only. Your numbers depend on your own volume and mix.
Common mistakes
- Watching only the dollar test and missing a rising claim-count share (or the reverse).
- Checking once at month end instead of monitoring as the month accumulates.
- Treating the line as an official guarantee rather than a threshold to monitor.
How PharmaFix helps
PharmaFix reads the report you already pull and estimates both the dollar and claim-count share, your effective rate, and your room remaining for the month, so you can review your position on your own schedule. It helps you monitor and understand the report; it does not provide legal or clinical advice and does not guarantee any outcome.
Frequently asked questions
Is 25% an official, fixed rule?
Treat it as a widely-discussed threshold, not legal advice. Networks set and change their own terms. Use it to monitor your own position, not as a guarantee.
Does the share reset each month?
The tests are typically read per calendar month, so the cumulative share starts over at the beginning of each month.
Estimate your report's position against the 25% reference line
Current checkout is test mode. Upload only an authorized PrimeRx or Caremark report without direct patient identifiers. PharmaFix calculates report-based rates and is designed not to retain report rows or results.